Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler

被引:20
|
作者
Abadelah, Mohamad [1 ]
Hazim, Firisteh [1 ]
Chrystyn, Henry [3 ]
Bagherisadeghi, Golshan [1 ]
Rahmoune, Hassan [2 ]
Larhrib, Hassan [1 ]
机构
[1] Univ Huddersfield, Dept Pharm & Pharmaceut Sci, Huddersfield HD1 3DH, W Yorkshire, England
[2] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge CB2 3RA, England
[3] Inhalat Consultancy Ltd, Leeds LS19 7SP, W Yorkshire, England
基金
英国工程与自然科学研究理事会;
关键词
Andersen Cascade impactor; Easyhaler; Formoterol; Inhaled volume; Maximum inhalation flow; LUNG DEPOSITION; CASCADE IMPACTOR; PARTICLE-SIZE; DEVICE DESIGN; PERFORMANCE; ASTHMA; COPD; AEROSOLIZATION; BUDESONIDE; SALBUTAMOL;
D O I
10.1016/j.ejps.2017.03.035
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most patients using dry powder inhalers (DPIs) do not achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of formoterol from an Easyhaler((R)) have been measured using the Andersen Cascade Impactor (ACI) with a maximum inhalation flow (MIF) of 28.3, 60 and 90 L/min and inhaled volumes (Vin) of 240, 750, 1500 and 2000 mL. The total emitted dose (TED) was significantly higher at 90 L/min (p < 0.05), but the difference in the TED between low (28.3 L/min) and high (90 L/min) flow rate was significantly reduced by increasing the Vin. The fine particle dose (FPD) was higher (p < 0.05) at 90 L/min for all Vin values compared to 28.3 and 60 L/min. Similarly the mass median aerodynamic diameter (MMAD) was smaller at 90 L/min across all Vin values. Dose emission characteristics were lower at 240 mL for both 1VIIFs. The results for 240 mL could be due to an insufficient Vin pulled through the ACI or incomplete emptying of the dose metering cup. This study shows that the FPD, %FPF and MMAD were not significantly affected by the vin >= 750 mL and that an inhaled volume as low as 750 mL could be used with the ACI.
引用
收藏
页码:180 / 187
页数:8
相关论文
共 50 条
  • [41] From laminar to turbulent flow in a dry powder inhaler: The effect of simple design modifications
    Singh, Gajendra
    Tang, Patricia
    Cheng, Shaokoon
    Chan, Hak-Kim
    Kourmatzis, Agisilaos
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 616
  • [42] Successful Use of Easyhaler® Dry Powder Inhaler in Patients with Chronic Obstructive Pulmonary Disease; Analysis of Peak Inspiratory Flow from Three Clinical Trials
    Kainu, Annette
    Vartiainen, Ville A.
    Mazur, Witold
    Hisinger-Molkanen, Hanna
    Lavorini, Federico
    Janson, Christer
    Andersson, Martin
    PULMONARY THERAPY, 2024, 10 (01) : 133 - 142
  • [43] Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols:: the in-vitro deposition and toxicity studies of the complexes
    Srichana, T
    Suedee, R
    Reanmongkol, W
    RESPIRATORY MEDICINE, 2001, 95 (06) : 513 - 519
  • [44] COMPARISON OF BRONCHODILATOR RESPONSES AND DEPOSITION PATTERNS OF SALBUTAMOL INHALED FROM A PRESSURIZED METERED DOSE INHALER, AS A DRY POWDER, AND AS A NEBULIZED SOLUTION
    ZAINUDIN, BMZ
    BIDDISCOMBE, M
    TOLFREE, SEJ
    SHORT, M
    SPIRO, SG
    THORAX, 1990, 45 (06) : 469 - 473
  • [45] Effect of physical properties of carrier particles on drug emission from a dry powder inhaler device
    Murakoshi, H
    Saotome, T
    Fujii, Y
    Ozeki, T
    Takashima, Y
    Yuasa, H
    Okada, H
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2005, 15 (03) : 223 - 226
  • [46] In vitro deposition from a dry powder inhaler and its correlation with surface energy of amorphous fine particle surfaces
    Oliveira, A. C.
    Buckton, G.
    Collins, E.
    Clarke, J.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 : A24 - A24
  • [47] Successful Use of Easyhaler® Dry Powder Inhaler in Patients with Chronic Obstructive Pulmonary Disease; Analysis of Peak Inspiratory Flow from Three Clinical Trials
    Annette Kainu
    Ville A. Vartiainen
    Witold Mazur
    Hanna Hisinger-Mölkänen
    Federico Lavorini
    Christer Janson
    Martin Andersson
    Pulmonary Therapy, 2024, 10 : 133 - 142
  • [48] Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler
    Chrystyn, Henry
    Safioti, Guilherme
    Keegstra, Johan Rene
    Gopalan, Gokul
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 491 (1-2) : 268 - 276
  • [49] FINE PARTICLE DOSE EMISSION OF A COMBINATION OF SALMETEROL (SX) AND FLUTICASONE PROPIONATE (FP) IN A DRY POWDER INHALER IS DEPENDENT OF THE ACCELERATION OF FLOW AND NOT INHALED VOLUME
    Khan, Y.
    Larhrib, H.
    Chrystyn, H.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (02) : A38 - A39
  • [50] The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation
    Chege, JK
    Chrystyn, H
    RESPIRATORY MEDICINE, 2000, 94 (01) : 51 - 56